معرفی
Durval Costa is a Principal Investigator at the Champalimaud Foundation, leading the Durval Costa Lab within the Nuclear Medicine - Radiopharmacology department. His research focuses on radiopharmaceutical development, quantitative imaging analysis, and radiation dosimetry for oncology and neuropsychiatry applications.
- Key Research Areas: SPECT/PET imaging, tumor phenotyping, personalized radiotherapy dosimetry, and computational analysis of functional abnormalities
- Collaborative Expertise: Integrates physics, mathematics, and clinical nuclear medicine
Recent Publications (2023-2025) highlight his work on deep learning in lesion segmentation, interhemispheric brain asymmetry in dementia, and standardization of digital/analog PET/CT scanners. Collaborations span oncology, neurology, and metabolic imaging domains.
Lab Team includes nuclear medicine physicians, mathematicians, physicists, and technicians working on:
- Developing MC simulation-based dosimetry
- Optimizing 18F-florbetaben for amyloid imaging
- Validating EARL1-compliant PET reconstruction protocols
- Investigating PSMA expression in thyroid pathology
۰مقاله منتشرشده
